251 related articles for article (PubMed ID: 17681665)
21. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
22. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow plasma cell infiltration in multiple myeloma.
de Gramont A; Benitez O; Smadja N; Brissaud P; Sirinelli A; Hubert D; Krulik M; Debray J
Br J Haematol; 1984 Jun; 57(2):351-3. PubMed ID: 6733051
[No Abstract] [Full Text] [Related]
24. Spindle cell lesion in the bone marrow.
Guzman S; Kitahara S
Blood; 2018 Sep; 132(10):1085. PubMed ID: 30190353
[No Abstract] [Full Text] [Related]
25. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
27. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.
Shah R; Stieltjes B; Andrulis M; Pfeiffer R; Sumkauskaite M; Delorme S; Schlemmer HP; Goldschmidt H; Landgren O; Hillengass J
Ann Hematol; 2013 Nov; 92(11):1553-7. PubMed ID: 23680869
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
29. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
30. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
31. [Mutual interaction between myeloma cells and bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
[No Abstract] [Full Text] [Related]
32. Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies.
Vercelli D; Di Guglielmo R; Guidi G; Scolari L; Buricchi L; Cozzolino F
Nouv Rev Fr Hematol (1978); 1980; 22(2):139-45. PubMed ID: 7422542
[TBL] [Abstract][Full Text] [Related]
33. [Non-secretory plasmacytoma. Bibliographic review and immunohistochemical study of a case].
Scolozzi R; Boccafogli A; Vicentini L; Coletti M; Dal Prà ML; Cavazzini L; Salmi R; Lanza M; Guidoboni CA; Tocchetto M
Minerva Med; 1985 Jun; 76(26-27):1279-84. PubMed ID: 3892370
[TBL] [Abstract][Full Text] [Related]
34. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.
Xu S; Evans H; Buckle C; De Veirman K; Hu J; Xu D; Menu E; De Becker A; Vande Broek I; Leleu X; Camp BV; Croucher P; Vanderkerken K; Van Riet I
Leukemia; 2012 Dec; 26(12):2546-9. PubMed ID: 22652628
[No Abstract] [Full Text] [Related]
35. [Cytochemical characteristics of lymphoid cells in patients with multiple myeloma].
Lugovskaia SA
Lab Delo; 1982; (11):643-6. PubMed ID: 6184523
[No Abstract] [Full Text] [Related]
36. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
37. Hypercupremia associated with a monoclonal immunoglobulin.
Lewis RA; Hultquist DE; Baker BL; Falls HF; Gershowitz H; Penner JA
J Lab Clin Med; 1976 Sep; 88(3):375-88. PubMed ID: 822110
[TBL] [Abstract][Full Text] [Related]
38. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
40. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
